Effect of Irbesartan on the level of serum high-sensitivity C-reactive protein in patients with acute cerebral infarction
Dai Wen-zhuo
Abstract
Dai Wen-zhuo
Abstract
Objective To study the effect of Irbesartan on the level of serum high-sensitivity C-reactive protein(hs-CRP) in the patients with acute cerebral infarction(ACI).Methods 60 patients with ACI were randomly assigned to Irbesartan therapy group(n=30) treated with Irbesartan 150 mg/d combined Aspirin 100 mg/d and conventional therapy group(n=30) treated with Aspirin 100 mg/d.Both groups were treated for 14 consecutive days and the other measures of symptomatic therapy were same.And another 30 patients without cerebrovascular diseases were selected as control group.The levels of serum hs-CRP were measured and the scores of neurological deficit(NDS) were evaluated before and after treatment.Results(1) Before treatment the levels of serum hs-CRP of ACI patients in both therapy groups were significantly higher than that in control group(all P0.01),and the level of serum hs-CRP was positively correlated with the NDS(r=0.34,P0.01).(2) After treatment the levels of serum hs-CRP and NDS in both therapy groups were significantly lower than those before treatment(all P0.01).(3) Deviation value of the serum hs-CRP between before and after treatment in Irbesartan therapy group was significantly higher than that in conventional therapy group(P0.05).Conclusion Irbesartan can significantly decrease the level of hs-CRP and improve the neurological function in the patients with ACI.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Objective To study the effect of Irbesartan on the level of serum high-sensitivity C-reactive protein(hs-CRP) in the patients with acute cerebral infarction(ACI).Methods 60 patients with ACI were randomly assigned to Irbesartan therapy group(n=30) treated with Irbesartan 150 mg/d combined Aspirin 100 mg/d and conventional therapy group(n=30) treated with Aspirin 100 mg/d.Both groups were treated for 14 consecutive days and the other measures of symptomatic therapy were same.And another 30 patients without cerebrovascular diseases were selected as control group.The levels of serum hs-CRP were measured and the scores of neurological deficit(NDS) were evaluated before and after treatment.Results(1) Before treatment the levels of serum hs-CRP of ACI patients in both therapy groups were significantly higher than that in control group(all P0.01),and the level of serum hs-CRP was positively correlated with the NDS(r=0.34,P0.01).(2) After treatment the levels of serum hs-CRP and NDS in both therapy groups were significantly lower than those before treatment(all P0.01).(3) Deviation value of the serum hs-CRP between before and after treatment in Irbesartan therapy group was significantly higher than that in conventional therapy group(P0.05).Conclusion Irbesartan can significantly decrease the level of hs-CRP and improve the neurological function in the patients with ACI.
Key concepts: Irbesartan, Medicine, C-reactive protein, Internal medicine, Aspirin, Gastroenterology, Cerebral infarction, Inflammation